Investors in Pharma

Invivo Partners, founded by Albert Ferrer and Luis Pareras, is a management company specializing in early-stage investments in the healthcare sector. They leverage a team of highly skilled professionals with expertise in scientific, technical, and financial analysis, supported by a strong network within the health ecosystem. Managed under Invivo Partners, Invivo Ventures operates based on the success of their initial fund, Healthequity, which closed at 60 million euros after registration with CNMV in 2019. Backed by prominent institutions and private investors, Invivo Partners has achieved notable exits and significant funding for their portfolio companies, emphasizing groundbreaking scientific innovations. Their strategic insights into Technology Transfer and ability to identify emerging trends position them as a leading player in Europe's Technology Transfer landscape.

Asabys Partners is a venture capital firm based in Barcelona that invests broadly in human healthcare. The firm is active in the health-tech and biopharma industries, targeting investments in Spain and internationally in highly innovative and transformative technologies. Motivated by the goal of pushing the boundaries of science and medicine, Asabys Partners sources and finances the most disruptive technologies and collaborates with top internal and external talents in the industry. With an entrepreneurial spirit, the firm seeks to be involved in the building and management of its companies, considering itself not just as investors, but as partners and collaborators to its portfolio companies.

They are a team of HealthTech entrepreneurs turned VC professionals who have founded laboratory groups, software companies, and tech companies. Now, they are looking to guide the next generation of HealthTech ventures.

Bioqube Ventures is a specialist life sciences investment firm based in Europe with a global footprint. They source, finance, and develop innovative therapeutic assets and technologies. They leverage their venture creation experience to translate and de-risk scientific innovation, advancing their investment portfolio and maximizing value for investors.

VIVES is a seed capital fund initiated by UCLouvain which invests in companies developing disruptive innovations with a positive societal impact. For more than 15 years, VIVES has invested in companies active in all technological sectors.

They are a life sciences venture capital fund that helps transform scientific innovation into products that positively impact people’s lives. Their extensive network and expertise in the sector allow them to contribute more than just capital. They aim to be part of the DNA of the new ventures they back.

The primary mission of Invest.BW is to sustainably support prosperity and entrepreneurial dynamism in Walloon Brabant. Invest.BW intervenes financially over the time horizon agreed together alongside entrepreneurs who will positively impact our province and in line with the economic, environmental and societal development desired for Wallonia. It aims for a fair return commensurate with the risk taken.

HealthCap is a European venture capital firm investing globally in life sciences and has raised eight funds since 1996. HealthCap has backed and built more than 127 companies, taken more than 45 companies public, and completed numerous trade sales. The investment strategy focuses on diseases with a high unmet medical need and breakthrough therapies that have the potential to be transformative, change clinical practice, and change the lives of patients suffering from these conditions.

Linc invests in product oriented companies in the Nordic Life Science industry – primarily in pharmaceutical and medical technology companies. Their investments in drug development usually take place at an early stage, while investments in medical technology are made in more mature businesses.

The Nordic region is at the forefront of the technology and scientific revolution. Northislet's vision is to help create and build Nordic champions within Life Science, allowing them to grow and reach their potential in the hands of local entrepreneurs, employees, and shareholders. Their goal is to create long-term value for all stakeholders, fostering a prosperous environment for new and existing companies, entrepreneurs, and scientists, making the Nordic region a competitive and attractive place for global talent within Life Science. Northislet aims to become a leading Nordic investment company in Life Science over the next 25 years, with the journey just beginning.

We focus on healthcare companies within pharma, biotech, medical technology and health care services and; technology companies within software and hardware. We are primarily interested when the capital and competence we add are required for product or market development. We make investments in companies which are still small and where we can make a difference as owners. We invest in several rounds of financing but limit our initial investment to SEK 10 million. We are looking for a high return which typically is achieved through and exit within 3-5 years. Our investors make a difference for the companies we invest in through the board.

Ysios Capital, a leading Spanish venture capital firm, provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies. Founded in 2008, Ysios Capital manages over USD 420M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies.